Connect with us

Hi, what are you looking for?

Jewish Business News

StartUps

Teva Launches Xeloda Generic Cancer Drug


According to IMS data Xeloda made by Genentech, had $754 million in US sales in 2013.

970803-xeloda

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces the launch of the generic equivalent to Xeloda (Capecitabine) Tablets, 150 MG and 500 MG, in the United States.

Xeloda is marketed by Genentech in the United States. Teva was the first to receive approval on its ANDA from the U.S. Food and Drug Administration on September 16, 2013 and is launching today per a settlement agreement.

Xeloda (Capecitabine) Tablets, 150 MG and 500 MG had annual sales of approximately $754 million in the United States, according to IMS data as of December, 2013.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Newsletter

Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

empty

The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Advertisement
cialis cialis satış